2017 was a landmark year in oncology. The FDA approved the first two CD19-targeted chimeric antigen receptor (CAR) T cell therapies: tisagenlecleucel-T (Kymriah; Novartis) and axicabtagene ciloleucel (Yescarta; Kite Pharma/Gilead Sciences). These therapies have remarkable efficacy in some blood cancers and herald a paradigm shift in oncology treatment…

Para acessar a publicação na íntegra clique aqui

NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | MARCH 2018 | 161